Business Wire

Coded Agency Celebrates Continued Growth with Rebrand, Internal Promotions and Client Wins

Share

Global modern communications company Coded Agency today announces a highly-anticipated, strategic overhaul of its branding and website following steady growth and innovation into new markets and industries.

Coded Agency, formerly known as codedpr, was founded in 2015 and quickly grew to become a leading agency of record for a range of lifestyle, fashion, beauty, fitness and wellness brands. In 2020, the agency generated a net income increase of 35%, despite an unprecedented global pandemic. Its upward trajectory continues in 2021 with not only a 65% increase in revenue in Q1 and a 50% increase in clients between Q1 and Q2, but a bold, fresh new look, instrumental employee promotions and expansion into Europe with the agency founder’s relocation to France.

The minority-owned, female-founded company renews its namesake as Coded Agency in tandem with a new website and branding designed by Designsake Studio, a San Francisco-based, award-winning and female founded design firm. “Coded Agency gets what it takes to build and support modern brands and we’re proud of our partnership with this women-owned and operated agency,” said Danielle McWaters, Founder & CCO of Designsake Studio.

Reflecting expansion into a more modern approach to communications that extends beyond traditional public relations and standard influencer programming, the new branding and positioning underscores the agency’s abilities to meet the evolving needs of its clients in a fast-changing world. The new website highlights the agency’s broad range of services including PR, influencer and celebrity marketing, event activations, partnerships and endorsements.

“Our goal for the redesign was to create a new brand identity that enhanced the visitor’s digital experience and showcased the results they deliver for their clients,” McWaters explained. “A fresh color palette, eye-catching typography and monochromatic photography communicate the agency’s tailored, edgy and purposeful approach to communications strategy,” McWaters continued.

Coded Agency prides itself on working with purposeful brands that embrace diversity, sustainability, inclusivity and female empowerment, aiming to amplify their stories. Most recently, Coded Agency has partnered with MVMT, premium watches and accessories; Scentbird, luxury fragrance subscription service; and niLuu, sustainably-made, PETA-approved vegan silk loungewear and sleep accessories, among other client wins. In addition, the agency is honored to continue ongoing partnerships with loyal clientele: Alleyoop, beauty and lifestyle brand; Vitality Institute, renowned beauty and wellness brand known for its chemical peel and medical-grade skincare products; and Caleres brands Allen Edmonds, Naturalizer and Blowfish Malibu.

“To meet the agency’s ongoing plans for growth, we have expanded key roles internally and are establishing a global presence with full-time team members located in Los Angeles, New York and France,” said Jennifer Wentzo, Coded Agency’s Founder and CEO. “Synergistic alignment with companies such as our existing client base and partners like Designsake Studio is part of our DNA. We are proud of our redesign and hope it reflects our forward-thinking approach to modern communications.”

Recent promotions include Jules Barker, appointed Vice President from Senior Director, and Jamie Hecht, named New York PR Manager from Senior Account Executive. In their new roles, they will manage agency operations, continue to foster team development, oversee the agency’s diverse client roster and spearhead the agency’s business development and East Coast representation, respectively.

About Coded Agency

Founded in 2015, Coded Agency is a modern, full-service marketing communications agency situated at the intersection of strategy, instinct and hustle. From dynamic startups to legacy brands under publicly traded parent companies in a diverse range of industries, the agency team delivers impactful, meaningful campaigns that help its brands grow. Consistently topping seven figures in annual revenue since 2016, the team dreams about what’s on the horizon while keeping an eye on the bottom line and infuses their work with the passion and dedication that is singular to the entrepreneurial spirit. For more information, visit www.codedagency.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jennifer Wentzo, Founder & CEO
info@codedagency.com
+1 424 333 2993

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 14:30:00 EEST | Press release

IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye